A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage)
NCT ID: NCT06741228
Last Updated: 2025-11-10
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE3
200 participants
INTERVENTIONAL
2024-12-11
2026-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study consists of a 12-week randomized, double-blind, single-dose administration period evaluating MM120 versus placebo, followed by a 40-week extension phase with the opportunity for open-label treatment. During this phase, participants will be monitored and evaluated for potential treatment with MM120 based on pre-specified safety and symptom severity criteria.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Arm 1 - Placebo
A substance that is designed to have no therapeutic value
Placebo
A substance that is designed to have no therapeutic value
Arm 2 - 100µg MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Placebo
A substance that is designed to have no therapeutic value
MM120 (LSD D-Tartrate)
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Male or female aged 18 to 74
3. HAM-A Total Score ≥20
Exclusion Criteria
2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder
3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)
4. Any clinically significant unstable illness
18 Years
74 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mind Medicine, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Lighthouse Psychiatry
Gilbert, Arizona, United States
Kadima Neuropsychiatry Institute
La Jolla, California, United States
UCSF Department of Neurology
San Francisco, California, United States
Psychedelic Science Institute
Santa Monica, California, United States
Mountain View
Denver, Colorado, United States
Clinical Neuroscience Solutions Inc.
Jacksonville, Florida, United States
Accel Research Sites - Lakeland CRU
Lakeland, Florida, United States
Segal Trials
Lauderhill, Florida, United States
Atlanta Center for Medical Research
Atlanta, Georgia, United States
iResearch Atlanta
Decatur, Georgia, United States
CenExel iResearch, LLC
Savannah, Georgia, United States
Uptown Research Institute
Chicago, Illinois, United States
Adams Clinical Boston
Boston, Massachusetts, United States
Adams Clinical Watertown
Watertown, Massachusetts, United States
University of Missouri Health Care
Columbia, Missouri, United States
Hassman Research Institute
Marlton, New Jersey, United States
Spectrum Neuroscience and Treatment Institute
New York, New York, United States
Adams Clinical Harlem
New York, New York, United States
New York State Psychiatric Institute (NYSPI)
New York, New York, United States
Adams Clinical Bronx
The Bronx, New York, United States
Cleveland Clinic Lutheran Hospital
Cleveland, Ohio, United States
Summit Headlands LLC
Portland, Oregon, United States
Scranton Medical Institute
Moosic, Pennsylvania, United States
Adams Clinical Philadelphia
Philadelphia, Pennsylvania, United States
Coastal Carolina Research Center
North Charleston, South Carolina, United States
Clinical Neuroscience Solutions, Inc.
Memphis, Tennessee, United States
Dell Medical School, University of Texas at Austin
Austin, Texas, United States
Austin Clinical Trial Partners
Austin, Texas, United States
BioBehavioral Research of Austin
Austin, Texas, United States
Cedar Clinical Research
Draper, Utah, United States
Memory Clinic Inc.
Bennington, Vermont, United States
Seattle Neuropsychiatric Treatment Center
Seattle, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Mind Medicine Clinical Trials Info Requests
Role: CONTACT
Phone: 332-282-0479
Email: [email protected]
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Matt Longson
Role: primary
Angelica Lau
Role: primary
Jennifer Mitchell, PhD
Role: primary
Keith Heinzerling
Role: primary
Kristen Johnson
Role: primary
Susan Angel
Role: primary
Katherine Prowse
Role: primary
Katie Prowse
Role: primary
Katie Prowse
Role: primary
Stephen Schneider
Role: primary
Allison Zadourian
Role: primary
Britlyn Brown
Role: primary
Lisa Speight
Role: primary
Simona Kobryn
Role: primary
Allison Zadourian
Role: primary
Adeen Izzathullah
Role: primary
Samantha Leonard
Role: backup
Allison Zadourian
Role: primary
Katelyn Schwesinger
Role: primary
Summit Research
Role: primary
Zoha Babar
Role: primary
Allison Zadourian
Role: primary
Brandy Dreyer
Role: primary
Charles Grandberry
Role: primary
Kelly Jackson
Role: primary
Cara Fonken
Role: primary
Janet Jimenez
Role: primary
Cynthia Murphy, PhD
Role: primary
Libby Kell
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MM120-300
Identifier Type: -
Identifier Source: org_study_id